when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

by stage

Marketed
Phase 3
Phase 2
Phase 1
Preclinical

browse

Most catalysts
Recently active
All drugs →
Companies
Patent cliff

what

Trial readouts
PDUFA dates
Approvals
Earnings

when

Upcoming
Month grid
Recently passed

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News
Drugs
Calendar
Companies

Hubs

Topics
Patent cliff
Publications
Readouts

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

GENENTECH · news · pharmadog

← back to GENENTECH

News mentioning GENENTECH

71 stories

1dVistagen cuts workforce for second time in 2026biospace

4dAnthropic's Nathan Frey on biopharma partners, M&A and pipelineendpoints

11dRoche puts numbers behind phase 3 kidney disease win amid blockbuster ambitionsfiercebiotech

12dRoche’s CEO has ‘absolutely not’ changed tune on Poseida despite scrapping CAR-T from the buyoutfiercebiotech

14dLycia aims for $228M IPO to generate data on food allergy rival to Xolairfiercebiotech

18dEx-Genentech scientist joins Ira Mellman at Medici; Intellia poaches CMO from Scholar Rockendpoints

20dWhy OMass’ $310M series C marks ‘fantastic milestone’ on journey to become ‘Britain’s Big Biotech’fiercebiotech

22dRoche sets sights on FDA approval decision of July 2027 with updated eye drug datafiercebiotech

22dMerck’s deeper dive into efficacy, safety of $1.3B eye disease drug raises fears of ‘limited’ potentialfiercebiotech

26dRobotics company Multiply Labs nets $75M; Isotope maker NorthStar gets up to $185Mendpoints

27dCerevance rescues its Parkinson's drug with phase 3 winfiercebiotech

28dBioSpace 40 Under 40 winners make their mark on biopharmabiospace

29dGenentech AI leader Richard Bonneau leaves pharma in latest exitendpoints

29dGenentech pens $1.27B deal to access Alector’s preclinical blood-brain barrier assetbiospace

29dOptogenetics researchers win a Nobel Prize; Roche bets on Alector brain drugbiopharma dive

29dGenentech pays Alector $100M for preclinical Parkinson’s prospectfiercebiotech

29dHow AI is transforming biopharma manufacturing facilities of the futurebiopharma dive

Oct 2, 26‘We’ve been taking our time’: Buzzy AI biotech Xaira reveals antibody platform, first taste of pipelinefiercebiotech

Oct 1, 26Chutes & Ladders—Bayer taps new chief medical officer; Cantor appointed PhRMA CEOfiercebiotech

Sep 29, 26Highlight Therapeutics illuminates positive ph. 2 topline data in high-risk skin cancerfiercebiotech

Sep 29, 26AI health startup Ortet launches with $500M and co-founders from Genentechendpoints

Sep 28, 26‘We’re so close to the tech companies’: Genentech CEO talks Fierce through vision for the futurefiercebiotech

Sep 28, 26Roche drops muscle-sparing obesity antibody after flunked interim analysisfiercebiotech

Sep 25, 26Genentech makes $1.5B+ deal with AI heavyweight Earendil for cancer bispecificsbiospace

Sep 25, 26Roche's Genentech inks $1.5B bispecific pact with fast-rising Earendilfiercebiotech

Sep 24, 26Roche inks up to $2B deal with Atavistik for new cardiometabolic drugsbiospace

Sep 24, 26Merck sees pivotal victory for $3B eye disease prospectfiercebiotech

Sep 22, 26‘It’s just survival now’: Why is almost a third of Boston’s life sciences lab space sitting vacant?fiercebiotech

Sep 22, 26Celldex monoclonal antibody rebounds with pair of phase 3 wins for chronic skin conditionfiercebiotech

Sep 17, 26Chutes & Ladders—Legend poaches Novartis vet to boost commercial potentialfiercebiotech

← prevpage 1 of 3next →